Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at HSBC

Equities research analysts at HSBC began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report issued on Monday, Marketbeat reports. The firm set a “buy” rating and a $255.00 price target on the biopharmaceutical company’s stock. HSBC’s price objective would indicate a potential downside of 67.61% from the company’s previous close.

REGN has been the subject of a number of other research reports. Sanford C. Bernstein raised their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Cantor Fitzgerald raised their price objective on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Royal Bank Of Canada increased their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $757.91.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $787.32 on Monday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $800.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The company’s 50-day moving average is $623.31 and its 200 day moving average is $579.16. The stock has a market capitalization of $82.75 billion, a P/E ratio of 18.85, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $12.46 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of REGN. Activest Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $27,000. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $31,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.